Table 2.
Repeated measures mixed modeling comparing the eszopiclone group to placebo group—main effects
| Sleep Diary V2 - V8 | β* | SE | t | p-value |
|---|---|---|---|---|
| Latency | −19.64 | 5.71 | −3.44 | 0.0008 |
| Awakenings | −0.81 | 0.20 | −4.00 | 0.0001 |
| Total Awake Time WASO | −11.81 | 8.41 | −1.41 | 0.1623 |
| Total Sleep Time | 28.13 | 13.63 | 2.06 | 0.0411 |
| Number of Naps | −0.02 | 0.05 | −0.38 | 0.7009 |
| Nap Time | −0.64 | 4.62 | −0.14 | 0.8897 |
| Actigraphy V2 - V8 | ||||
| Number of awakenings | −0.62 | 1.56 | −0.40 | 0.6928 |
| Sleep efficiency | 2.15 | 1.44 | 1.50 | 0.1370 |
| Wake time after sleep onset | 4.00 | 3.56 | 1.12 | 0.2639 |
| Total sleep time | 8.98 | 10.45 | 0.86 | 0.3919 |
| SI V1 - V8 | ||||
| ISI Total Score | −4.41 | 1.43 | −3.09 | 0.0024 |
| ISI Improvement (6-point drop) V3-V8 (Y/N) | 7.21† | (1.51,34.4)† | 2.50 | 0.0136 |
| HRSD V1 - V8 | ||||
| 24-Item Hamilton | −3.50 | 1.46 | −2.40 | 0.0177 |
| 21-Question Hamilton | −2.20 | 1.36 | −1.62 | 0.1064 |
| CGI | ||||
| CGI Severity V1-V8 | −0.52 | 0.22 | −2.36 | 0.0194 |
| CGI Improvement V3-V8 | −0.46 | 0.20 | −2.30 | 0.0229 |
V refers to Visit;
*
Models adjusted for treatment, time, baseline values, age, gender;
†
Adjusted odds ratio and 95% confidence interval.